Details of the Drug
General Information of Drug (ID: DMV6WC4)
Drug Name |
4-phenyl-1,2,3,6-tetrahydropyridine
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
4-Phenyl-1,2,3,6-tetrahydropyridine; 10338-69-9; 4-Phenyl-1,2,3,6-tetrahydro-pyridine; 1,2,3,6-tetrahydro-4-phenyl-pyridine; 1,2,3,6-Tetrahydro-4-phenylpyridine; Pyridine, 1,2,3,6-tetrahydro-4-phenyl-; CHEMBL6224; OMPXTQYWYRWWPH-UHFFFAOYSA-N; 4-phenyl-1,2,3,6-tetrahydro pyridine; Oprea1_874761; NSC 54451; AC1Q1IN6; AC1L33NE; AC1Q1GX2; SCHEMBL415545; DTXSID2065040; CTK4A2038; MolPort-001-794-494; 43064-12-6 (hydrochloride); ZINC1295150; NSC54451; 4-Phenyl-1,3,6-tetrahydropyridine; STK535809; NSC-54451; BDBM50036718; BBL027886
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 159.23 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 2 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 1 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 1 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References